New England Surgical Society (NESS)
Search NESS
  Home
  Annual Meeting
  Annual Resident and Fellow Research Day
  Members
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Awards
  Journal of the American College of Surgeons
  Newsletters
  Committees
  Contact NESS

2008 Annual Meeting Abstracts


Novel Therapeutic Approaches to Premature Lung Disease Utilizing Stem Cells

Christine Finck, MD1,2, Blair Roszell1, Ariel Seaton1, Guo-Hua Fong, PhD2.
1Connecticut Children's Medical Center, Hartford, CT, USA, 2University of Connecticut Health Center, Hartford, CT, USA.

Objective: Each week in Connecticut, 81 babies are born prematurely. These preterm newborns have pulmonary hypoplasia(PH) with a mortality as high as 91%. PH is characterized by poorly differentiated alveolar epithelium, reduced alveolar type 2 cells (AE2) and decreased surfactant production. Recently we demonstrated a method for deriving AE2-like cells from pluripotent murine embryonic stem cells (mESC). We hypothesize that these differentiated cells can be intra-tracheally administered into a mouse and incorporate into the recipient lung parenchyma. This represents a first step toward stem cell based treatment of PH.
Design: CD4-Foxa2/GFP-Bry murine ESCs (mESC) were cultured in Activin A and switched to media containing bFGF, yielding 12.4% surfactant protein C (SpC) expressing cells(AE2). These cells were suspended in media (100,000 cells/ml). Adult 129 mice were anesthetized and 0.1ml of cells or saline (control) was injected intratracheally through a 27 guage needle. The lungs from the recipient mice were harvested and fixed after 7 days.
Outcome Measures: Immunohistochemical identification of lung intra-parenchymal mESC-derived AE2 cells using antibodies for SpC (red) and CD4 (green) with nuclear BBZ counterstaining. Double staining (yellow) identifies intratracheally administered mESC derived AE2 cells.
Results: Incorporation of ESC-derived AE2 cells within the host lung parenchyma (arrow) was evident. The cells were located in the distal alveoli and did not aggregate in the proximal airways.
Conclusions: We demonstrate that delivery of mESC derived AE2 cells is feasible with intratracheal injection. This represents the first step towards translational research with site-specific delivery for a stem cell-based therapeutic approach towards PH.


 

Copyright © 2018 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.